Citi lowered the firm’s price target on Health Catalyst (HCAT) to $6.50 from $7 and keeps a Buy rating on the shares. The firm expects another volatile earnings season for its health tech coverage. Health tech companies should be well-insulated from tariffs and a potential recession, which would lead to less earnings volatility this year versus the broader market, however, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target lowered to $5 from $7 at KeyBanc
- Health Catalyst downgraded to In Line from Outperform at Evercore ISI
- Health Catalyst: A Strategic Buy Amidst Promising Growth and Platform Potential
- Health Catalyst: A Buy Opportunity Amidst Market Overreaction and Promising Growth Prospects
- Strategic Growth and Profitability Outlook for Health Catalyst: Analyst Recommends with $10 Price Target